Runben Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 266 million yuan, a year-on-year increase of 1.98%

According to the Zhitong Finance APP, Runben Biotechnology disclosed its third-quarter report for 2025. The company achieved revenue of 1.238 billion yuan in the first three quarters, a year-on-year increase of 19.28%; the net profit attributable to shareholders of the listed company was 266 million yuan, a year-on-year increase of 1.98%; the net profit excluding non-recurring gains and losses was 251 million yuan, a year-on-year decrease of 1.79%; the basic earnings per share were 0.66 yuan